Rocket Pharmaceuticals, Inc.
RCKT
$8.32
-$0.14-1.66%
| Weiss Ratings | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.22 | |||
| Price History | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.34% | |||
| 30-Day Total Return | -25.98% | |||
| 60-Day Total Return | -26.70% | |||
| 90-Day Total Return | -52.67% | |||
| Year to Date Total Return | -34.59% | |||
| 1-Year Total Return | -70.14% | |||
| 2-Year Total Return | -52.91% | |||
| 3-Year Total Return | -44.97% | |||
| 5-Year Total Return | -35.95% | |||
| 52-Week High % Change | -70.49% | |||
| 52-Week Low % Change | 4.96% | |||
| Price | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $28.67 | |||
| 52-Week Low Price | $8.06 | |||
| 52-Week Low Price (Date) | Mar 11, 2025 | |||
| 52-Week High Price (Date) | Mar 21, 2024 | |||
| Valuation | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 902.09M | |||
| Enterprise Value | 555.25M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.73 | |||
| Earnings Per Share Growth | -7.00% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.94 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $8.32 | |||
| Enterprise Value/EBITDA (TTM) | -2.10 | |||
| Enterprise Value/EBIT | -2.03 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 97.53M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 609 659 8001 | |||
| Address | 9 Cedarbrook Drive Cranbury, NJ 08512 | |||
| Website | www.rocketpharma.com | |||
| Country | United States | |||
| Year Founded | 1999 | |||
| Profitability | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -31.22% | |||
| Return on Equity | -- | |||
| Income Statement | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -263.83M | |||
| EBIT (TTM) | -273.21M | |||
| Net Income (TTM) | -258.75M | |||
| Net Income Avl. to Common (TTM) | -258.75M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -1.12% | |||
| EPS Diluted (TTM) | -2.73 | |||
| EPS Diluted Growth (Q YOY) | 3.24% | |||
| Balance Sheet | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 372.34M | |||
| Cash Per Share (Q) | $3.82 | |||
| Total Current Assets (Q) | 378.18M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 463.23M | |||
| Current Ratio (Q) | 9.296 | |||
| Book Value Per Share (Q) | $4.35 | |||
| Total Assets (Q) | 527.70M | |||
| Total Current Liabilities (Q) | 40.68M | |||
| Total Debt (Q) | 25.50M | |||
| Total Liabilities (Q) | 64.47M | |||
| Total Common Equity (Q) | 463.23M | |||
| Cash Flow | RCKT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 131.71M | |||
| Cash from Financing (TTM) | 185.74M | |||
| Net Change in Cash (TTM) | 107.72M | |||
| Levered Free Cash Flow (TTM) | -133.26M | |||
| Cash from Operations (TTM) | -209.72M | |||
